Bispecific therapies require clearer terminology to improve safety and communication.
Kelly M. Brunk, PharmD, BCOP
Advertisement
Articles by Kelly M. Brunk, PharmD, BCOP
Current guideline recommendations include various combinations of targeted therapy with immunotherapy.
In June 2020, the FDA granted a fast track designation to fruquintinib for patients with mCRC previously treated with other therapies.
Advertisement
Latest Updated Articles
The Term 'Bispecific Antibody' Is No Longer EnoughJune 16th 2025
Advertisement
Advertisement
Trending on Pharmacy Times
1
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
4
Up to 5 Cups of Coffee Daily Safe—and Beneficial—for Most Adults
5